Document Detail


Adjunctive pregabalin in partial responders with major depressive disorder and residual anxiety.
MedLine Citation:
PMID:  23277244     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Anxiety symptoms in depression result often in treatment resistance, residual symptoms, and persistent functional impairment.
OBJECTIVE: To assess the effectiveness and safety of adjunctive pregabalin to antidepressants for residual anxiety in patients with major depressive disorder (MDD).
METHODS: A retrospective chart review was conducted to identify partial responders among patients with MDD with residual anxiety. Twenty such patients (age, 58.4 ± 11.2 years; 15 women; baseline Hamilton Depression Rating Scale [HDRS], 17.1 ± 3.5) who received adjunctive pregabalin for residual anxiety were included. Antidepressants augmented were the selective serotonin reuptake inhibitors (n = 12), mirtazapine (n = 2), and selective serotonin-norepinephrine reuptake inhibitors (n = 6).
RESULTS: Twenty patients received at least 4 weeks of pregabalin treatment after 8 weeks of antidepressant therapy. At week 1 (9 weeks after initiating treatment), pregabalin was prescribed at a mean ± SD dose of 71.2 ± 31.7 mg, and the mean maximum pregabalin dose prescribed was 156.2 ± 76.5 mg (range, 75-300 mg). At week 8, there were 13 responders (13/20 [65%]), and 7 of these 13 patients achieved remission (HDRS17 < 8). There were significant decreases in HDRS scores (13.5 ± 3.1 vs 9.1 ± 2.9, P < 0.000), and HDRS anxiety/somatization subscale scores (6.3 ± 2 to 3.6 ± 1.7, P < 0.000). Adverse effects included somnolence (n = 7), weight gain (n = 3), dizziness (n = 4), dry mouth (n = 6), edema (n = 3), blurred vision (n = 3), difficulty with concentration/attention (n = 8), headache (n = 6), and diarrhea (n = 5).
CONCLUSIONS: The results suggest a possible augmentation role for pregabalin when used in conjunction with conventional antidepressants for residual anxiety in MDD.
Authors:
Mario Vitali; Enrico Tedeschini; Martino Mistretta; Kiki Fehling; Franca Aceti; Mauro Ceccanti; Maurizio Fava
Related Documents :
22988824 - Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis.
24731184 - Effects of verbal ability and severity of autism on anxiety in adolescents with asd: on...
24529814 - The prospective role of defeat and entrapment in depression and anxiety: a 12-month lon...
23793274 - Personality profiles of patients with dysthymic and panic disorder.
8320624 - Predictors of outcome of severe respiratory syncytial virus-associated respiratory fail...
24409034 - The reliability and validity of the clinical competence evaluation scale in physical th...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of clinical psychopharmacology     Volume:  33     ISSN:  1533-712X     ISO Abbreviation:  J Clin Psychopharmacol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  2013-06-12     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  8109496     Medline TA:  J Clin Psychopharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  95-8     Citation Subset:  IM    
Affiliation:
Department of Clinical Medicine, Sapienza-University of Rome, Rome, Italy. vitalimario@yahoo.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic Agents / adverse effects,  therapeutic use*
Aged
Anti-Anxiety Agents / adverse effects,  therapeutic use*
Anxiety / diagnosis,  drug therapy*,  psychology
Depressive Disorder, Major / diagnosis,  drug therapy*,  psychology
Female
Humans
Male
Middle Aged
Psychiatric Status Rating Scales
Retrospective Studies
Serotonin Uptake Inhibitors / adverse effects,  therapeutic use*
Time Factors
Treatment Outcome
gamma-Aminobutyric Acid / adverse effects,  analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Adrenergic Agents; 0/Anti-Anxiety Agents; 0/Serotonin Uptake Inhibitors; 55JG375S6M/pregabalin; 56-12-2/gamma-Aminobutyric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Schizophrenia past clozapine: what works?
Next Document:  Acute Antidepressive Efficacy of Lithium Monotherapy, Not Citalopram, Depends on Recurrent Course of...